amitriptyline has been researched along with Lassitude in 23 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Excerpt | Relevance | Reference |
---|---|---|
"Amitriptyline is an established medication used off-label for the treatment of fibromyalgia, but pregabalin, duloxetine, and milnacipran are the only pharmacological agents approved by the US Food and Drug Administration (FDA) to treat fibromyalgia." | 9.22 | Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis. ( Doucette, JA; Eguale, T; Farag, HM; Goswami, H; Sultan, I; Yunusa, I, 2022) |
"To determine the effects of bedtime very low dose (VLD) cyclobenzaprine (CBP) on symptoms and sleep physiology of patients with fibromyalgia (FM), unrefreshing sleep, and the α-nonREM sleep electroencephalographic (EEG) anomaly at screening." | 9.15 | Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. ( Archambault, WT; Harris, HW; Kwong, T; Lederman, S; Moldofsky, H, 2011) |
"We performed a double-blind, placebo-controlled study to investigate the effectiveness of amitriptyline for the prophylactic treatment of patients with acute thalamic stroke in preventing central poststroke pain." | 9.10 | Amitriptyline in the prophylaxis of central poststroke pain. Preliminary results of 39 patients in a placebo-controlled, long-term study. ( Lampl, C; Röper, C; Yazdi, K, 2002) |
"A double blind, placebo controlled, crossover design study examined overnight sleep physiology, pain, fatigue, and mood symptoms in 12 patients with fibromyalgia treated with cyclobenzaprine." | 9.07 | The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. ( Lue, FA; Moldofsky, H; Reynolds, WJ; Saskin, P, 1991) |
"To systematically review the effectiveness of cyclobenzaprine in the treatment of fibromyalgia." | 8.82 | Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. ( Jackson, JL; O'Malley, PG; Tofferi, JK, 2004) |
"Amitriptyline is an established medication used off-label for the treatment of fibromyalgia, but pregabalin, duloxetine, and milnacipran are the only pharmacological agents approved by the US Food and Drug Administration (FDA) to treat fibromyalgia." | 5.22 | Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis. ( Doucette, JA; Eguale, T; Farag, HM; Goswami, H; Sultan, I; Yunusa, I, 2022) |
"To determine the effects of bedtime very low dose (VLD) cyclobenzaprine (CBP) on symptoms and sleep physiology of patients with fibromyalgia (FM), unrefreshing sleep, and the α-nonREM sleep electroencephalographic (EEG) anomaly at screening." | 5.15 | Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. ( Archambault, WT; Harris, HW; Kwong, T; Lederman, S; Moldofsky, H, 2011) |
"Peak power and fatigue index increased, and VO(2max) and VT did not change with both fluoxetine and amitriptyline." | 5.12 | Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia. ( Gökbel, H; Levendoğlu, F; Okudan, N; Ozerbil, O, 2006) |
"We performed a double-blind, placebo-controlled study to investigate the effectiveness of amitriptyline for the prophylactic treatment of patients with acute thalamic stroke in preventing central poststroke pain." | 5.10 | Amitriptyline in the prophylaxis of central poststroke pain. Preliminary results of 39 patients in a placebo-controlled, long-term study. ( Lampl, C; Röper, C; Yazdi, K, 2002) |
"A double blind, placebo controlled, crossover design study examined overnight sleep physiology, pain, fatigue, and mood symptoms in 12 patients with fibromyalgia treated with cyclobenzaprine." | 5.07 | The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. ( Lue, FA; Moldofsky, H; Reynolds, WJ; Saskin, P, 1991) |
"Amitriptyline 25-50 mg/day reduces pain, fatigue, and depressiveness in patients with FMS and improves sleep and quality of life." | 4.84 | A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. ( Häuser, W; Sommer, C; Uçeyler, N, 2008) |
"To systematically review the effectiveness of cyclobenzaprine in the treatment of fibromyalgia." | 4.82 | Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. ( Jackson, JL; O'Malley, PG; Tofferi, JK, 2004) |
"There were 1948 treatment histories for modafinil and 1394 treatment reports for amitriptyline reported across five PatientsLikeMe communities (multiple sclerosis, Parkinson's disease, mood conditions, fibromyalgia/chronic fatigue syndrome, and amyotrophic lateral sclerosis)." | 3.77 | Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe. ( Frost, J; Heywood, J; Okun, S; Vaughan, T; Wicks, P, 2011) |
"12%) in the amitriptyline group and paresthesia (31% vs." | 2.84 | Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. ( Chamberlin, LA; Coffey, CS; Ecklund, DJ; Hershey, AD; Klingner, EA; Korbee, LL; Porter, LL; Powers, SW; Yankey, JW, 2017) |
" The dosage was 150 mg daily in both treatment groups." | 2.65 | Nomifensine and amitriptyline in the treatment of depression. A multi-centre double-blind comparison. ( Agren, H; Bjaring, B; Källström, B; Lund, M; Månsby, J; Peterson, LE; Roos, BE; Wistedt, B, 1983) |
"Amitriptyline was found to have the greatest effect in reducing attacks with a short warning and in which no specific cause could be recognized." | 2.64 | Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. ( Gomersall, JD; Stuart, A, 1973) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 11 (47.83) | 18.7374 |
1990's | 1 (4.35) | 18.2507 |
2000's | 4 (17.39) | 29.6817 |
2010's | 5 (21.74) | 24.3611 |
2020's | 2 (8.70) | 2.80 |
Authors | Studies |
---|---|
Farag, HM | 1 |
Yunusa, I | 1 |
Goswami, H | 1 |
Sultan, I | 1 |
Doucette, JA | 1 |
Eguale, T | 1 |
Bakker, MH | 1 |
Hugtenburg, JG | 1 |
Smits, MG | 1 |
van der Horst, HE | 1 |
Slottje, P | 1 |
Macfarlane, GJ | 1 |
Kronisch, C | 1 |
Dean, LE | 1 |
Atzeni, F | 1 |
Häuser, W | 2 |
Fluß, E | 1 |
Choy, E | 1 |
Kosek, E | 1 |
Amris, K | 1 |
Branco, J | 1 |
Dincer, F | 1 |
Leino-Arjas, P | 1 |
Longley, K | 1 |
McCarthy, GM | 1 |
Makri, S | 1 |
Perrot, S | 1 |
Sarzi-Puttini, P | 1 |
Taylor, A | 1 |
Jones, GT | 1 |
Powers, SW | 1 |
Coffey, CS | 1 |
Chamberlin, LA | 1 |
Ecklund, DJ | 1 |
Klingner, EA | 1 |
Yankey, JW | 1 |
Korbee, LL | 1 |
Porter, LL | 1 |
Hershey, AD | 1 |
Rheker, J | 1 |
Winkler, A | 1 |
Doering, BK | 1 |
Rief, W | 1 |
Uçeyler, N | 1 |
Sommer, C | 1 |
Frost, J | 1 |
Okun, S | 1 |
Vaughan, T | 1 |
Heywood, J | 1 |
Wicks, P | 1 |
Moldofsky, H | 2 |
Harris, HW | 1 |
Archambault, WT | 1 |
Kwong, T | 1 |
Lederman, S | 1 |
Lampl, C | 1 |
Yazdi, K | 1 |
Röper, C | 1 |
Tofferi, JK | 1 |
Jackson, JL | 1 |
O'Malley, PG | 1 |
Ozerbil, O | 1 |
Okudan, N | 1 |
Gökbel, H | 1 |
Levendoğlu, F | 1 |
Wistedt, B | 1 |
Agren, H | 1 |
Bjaring, B | 1 |
Källström, B | 1 |
Lund, M | 1 |
Månsby, J | 1 |
Peterson, LE | 1 |
Roos, BE | 1 |
Kampman, R | 1 |
Nummikko-Pelkonen, A | 1 |
Kuha, S | 1 |
Reynolds, WJ | 1 |
Saskin, P | 1 |
Lue, FA | 1 |
Hartmann, E | 2 |
Cravens, J | 2 |
Barton, JL | 1 |
Snaith, RP | 1 |
Gomersall, JD | 1 |
Stuart, A | 1 |
Deberdt, R | 1 |
Luzecky, MH | 1 |
Burman, KD | 1 |
Schultz, ER | 1 |
Malitz, S | 1 |
Kanzler, M | 1 |
Pieschl, D | 1 |
Richtberg, W | 1 |
Brüning, J | 1 |
Ekdawi, MY | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Benefits of Kinesio Taping and Inhibitory Treatment Techniques in Patients With Fibromyalgia Syndrome[NCT02859467] | 64 participants (Anticipated) | Interventional | 2016-08-31 | Suspended | |||
Museums as Health Spaces: Design and Evaluation of the Effectiveness of an Arts in Health Intervention to Improve the Quality of Life and Functional Capacity Regarding the Pain of People With Fibromyalgia. Mixed Methodology Study.[NCT05993663] | 121 participants (Anticipated) | Interventional | 2023-10-02 | Recruiting | |||
Effects of Manipulative Therapy in the Lower Thoracic and Cervical Spine in Subjects With Fibromyalgia Syndrome[NCT02864524] | 64 participants (Anticipated) | Interventional | 2016-08-31 | Active, not recruiting | |||
Effectiveness of Pain Neuroscience Education and Strength Training Program in Patients With Fibromyalgia[NCT04855851] | 60 participants (Anticipated) | Interventional | 2022-03-01 | Recruiting | |||
A Pilot Study of Small Fiber Neuropathy Prevalence in Fibromyalgia Patients Compared to Healthy Subjects Using Sudoscan®[NCT03347669] | 100 participants (Anticipated) | Interventional | 2017-11-06 | Recruiting | |||
Effectiveness of High-intensity Interval Training Combined With Resistance Training in Patients With Fibromyalgia[NCT03924960] | 55 participants (Actual) | Interventional | 2019-04-22 | Completed | |||
Effectiveness of Spinal Manipulation in Addition to Standard Pharmacological Treatment in Fibromyalgia : A Blinded Randomized Clinical Trial[NCT04673058] | 60 participants (Actual) | Interventional | 2021-01-26 | Completed | |||
Amitriptyline and Topiramate in the Prevention of Childhood Migraine[NCT01581281] | Phase 3 | 488 participants (Actual) | Interventional | 2012-06-30 | Terminated (stopped due to Interim assessment provided sufficient data to answer study questions) | ||
Evaluation of the Efficiency of a Therapeutic Education Program in Standardized Thermal Cure for Fibromyalgia Patients[NCT02406313] | 152 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The PedMIDAS scale which evaluated the impact of headaches in school, home, play, and social activities, is comprised of six items that pertain to days missed in various activities over the past 90 days. Questions were answered by the youth in consultation with their parents and reviewed by study staff. The PedMIDAS scale was administered at baseline (covering the three months prior to enrollment) and at the 24-week endpoint visit (the end of the maintenance period, covering three months of enrollment). A total PedMIDAS score (sum of items 1-6) was used in this trial. Scores range from 0-240; with a score of 0-10 indicating no disability, 11-30 mild disability, 31-50 moderate disability, and more than 50 severe disability in daily activities. The main outcome measure for this comparison will be the difference in the baseline and endpoint (24 week) PedMIDAS total scores for:~Amitriptyline vs. Placebo~Topiramate vs. Placebo~Amitriptyline vs Topiramate" (NCT01581281)
Timeframe: baseline and 24 week endpoint
Intervention | units on a scale (Mean) |
---|---|
Topiramate | -26.8 |
Placebo | -22.6 |
Amitriptyline | -22.5 |
"This outcomes measure examines whether the rate of absolute number of headache days, per 28 day period, differs between treatment groups over time. This was assessed longitudinally based on the actual number of headache days from the 28 days prior to randomization to the last 28 days of this 24 week trial. The change in absolute headache days was compared between:~Amitriptyline vs. placebo~Topiramate vs. placebo~Amitriptyline vs. Topiramate" (NCT01581281)
Timeframe: 4 week baseline period and last 4 weeks of the 24-week trial
Intervention | days (Mean) |
---|---|
Topiramate | -6.7 |
Placebo | -5.9 |
Amitriptyline | -6.7 |
"The primary endpoint was a ≥ 50% reduction in headache frequency from the 28 days (4 weeks) baseline period prior to randomization to the last 28 days (4 weeks) of the trial. Headache frequency was defined as the number of days with headache for a given four week 28 day (4 week) period. A headache day was defined as any day during which any headache occurs within a 24 hour period, starting and ending at midnight.~For each participant, the primary endpoint involved a determination of whether a 50% or greater reduction in headache frequency was observed during the last 4 weeks of active treatment as compared with the headache frequency during the 4-week baseline period. Results were compared across the three treatment groups." (NCT01581281)
Timeframe: 4 week baseline period and last 4 weeks of the 24-week trial
Intervention | Participants (Count of Participants) |
---|---|
Topiramate | 72 |
Placebo | 40 |
Amitriptyline | 69 |
To determine if amitriptyline or topiramate differ from placebo on the occurrence of treatment emergent serious adverse events. (NCT01581281)
Timeframe: 24 weeks of the trial
Intervention | serious adverse events (Number) |
---|---|
Topiramate | 4 |
Placebo | 2 |
Amitriptyline | 6 |
To assess tolerability, the percentage of subjects who complete the entire 24-week treatment period will be estimated in each of the three groups. (NCT01581281)
Timeframe: 24 weeks
Intervention | Participants (Count of Participants) |
---|---|
Topiramate | 102 |
Placebo | 59 |
Amitriptyline | 106 |
4 reviews available for amitriptyline and Lassitude
Article | Year |
---|---|
Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis.
Topics: Amitriptyline; Duloxetine Hydrochloride; Fatigue; Female; Fibromyalgia; Humans; Male; Middle Aged; M | 2022 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
EULAR revised recommendations for the management of fibromyalgia.
Topics: Activities of Daily Living; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroi | 2017 |
A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome.
Topics: Amitriptyline; Antidepressive Agents; Databases, Bibliographic; Depression; Fatigue; Fibromyalgia; H | 2008 |
Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis.
Topics: Amitriptyline; Databases, Factual; Fatigue; Female; Fibromyalgia; Humans; Male; Middle Aged; Muscle | 2004 |
13 trials available for amitriptyline and Lassitude
Article | Year |
---|---|
Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine.
Topics: Adolescent; Amitriptyline; Anticonvulsants; Child; Double-Blind Method; Fatigue; Female; Fructose; H | 2017 |
Learning to experience side effects after antidepressant intake - Results from a randomized, controlled, double-blind study.
Topics: Adult; Amitriptyline; Antidepressive Agents; Cardiovascular Diseases; Conditioning, Classical; Depre | 2017 |
Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study.
Topics: Adult; Aged; Amitriptyline; Double-Blind Method; Electroencephalography; Fatigue; Female; Fibromyalg | 2011 |
Amitriptyline in the prophylaxis of central poststroke pain. Preliminary results of 39 patients in a placebo-controlled, long-term study.
Topics: Acute Disease; Adult; Aged; Amitriptyline; Analgesics, Non-Narcotic; Antidepressive Agents, Tricycli | 2002 |
Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia.
Topics: Adult; Amitriptyline; Antidepressive Agents; Cross-Over Studies; Double-Blind Method; Exercise Test; | 2006 |
Nomifensine and amitriptyline in the treatment of depression. A multi-centre double-blind comparison.
Topics: Adult; Aged; Amitriptyline; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Fati | 1983 |
Tricyclic antidepressants in the treatment of depressions. A double-blind clinical comparison of clomipramine (Anafranil) and amitriptyline.
Topics: Adult; Aged; Ambulatory Care; Amitriptyline; Clinical Trials as Topic; Clomipramine; Depression; Dib | 1978 |
The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia.
Topics: Adult; Affect; Amitriptyline; Double-Blind Method; Fatigue; Female; Fibromyalgia; Humans; Male; Midd | 1991 |
The effects of long term administration of psychotropic drugs on human sleep. II. The effects of reserpine.
Topics: Adult; Amitriptyline; Chloral Hydrate; Chlordiazepoxide; Chlorpromazine; Clinical Trials as Topic; D | 1973 |
The effects of long term administration of psychotropic drugs on human sleep. 3. The effects of amitriptyline.
Topics: Adult; Amitriptyline; Chloral Hydrate; Chlordiazepoxide; Chlorpromazine; Clinical Trials as Topic; D | 1973 |
A clinical assessment of a sustained release preparation of amitriptyline.
Topics: Administration, Oral; Adult; Amitriptyline; Delayed-Action Preparations; Depression; Fatigue; Hospit | 1972 |
Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial.
Topics: Adult; Aged; Amitriptyline; Evaluation Studies as Topic; Fatigue; Female; Humans; Male; Middle Aged; | 1973 |
Are antidepressants better than placebo?
Topics: Adjustment Disorders; Adult; Aged; Amitriptyline; Antidepressive Agents; Anxiety; Clinical Trials as | 1971 |
6 other studies available for amitriptyline and Lassitude
Article | Year |
---|---|
Off-label low dose amitriptyline for insomnia disorder: Patient-reported outcomes.
Topics: Amitriptyline; Cross-Sectional Studies; Fatigue; Humans; Off-Label Use; Patient Reported Outcome Mea | 2023 |
Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe.
Topics: Amitriptyline; Amyotrophic Lateral Sclerosis; Benzhydryl Compounds; Cognition Disorders; Community N | 2011 |
Lorazepam in the treatment of severe anxiety and anxiety associated with psychotic conditions.
Topics: Adult; Aggression; Amitriptyline; Anxiety Disorders; Ataxia; Benzodiazepinones; Bipolar Disorder; Ch | 1973 |
The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline administration.
Topics: Amitriptyline; Cognition Disorders; Fatigue; Female; Humans; Hyponatremia; Middle Aged; Osmolar Conc | 1974 |
[Saroten retard and its therapeutic possibilities in chronic schizophrenic psychoses. Results of clinical-experimental tests].
Topics: Adult; Amitriptyline; Body Weight; Cardiovascular Diseases; Chronic Disease; Delayed-Action Preparat | 1971 |
Dibenzepin and amitriptyline in the treatment of depression.
Topics: Adult; Amitriptyline; Anorexia Nervosa; Constipation; Depression; Dibenzazepines; Fatigue; Humans; P | 1971 |